A Phase 1 Study Combining MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

Trial Profile

A Phase 1 Study Combining MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Irinotecan (Primary) ; MM-151 (Primary) ; Fluorouracil; Folinic acid
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jan 2017 According to a Merrimack Pharmaceuticals media release, company discontinued this study until conditions are appropriate to invest in this study.
    • 08 Jan 2017 Status changed from recruiting to discontinued, as per a Merrimack Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top